Article Document Academic Article Information Content Entity Continuant Continuant Journal Article Entity Entity Generically Dependent Continuant 2025-05-08T09:04:44 RDF description of Can faster aspart be used to optimize glycemic control with insulin pump therapy? From expectations to lessons learned after a year of use in the United States - http://repository.healthpartners.com/individual/document-rn46011 public Monitoring, Physiologic 4 Blood 23948 Diabetes Clinical Diabetes 40 2025-03-31T21:26:45.114-05:00 <p>Fast-acting insulin aspart (faster aspart) is an ultra-rapid-acting formulation of insulin aspart developed to more closely match the prandial endogenous insulin profile, and its accelerated absorption kinetics are expected to provide clinical benefits for patients using insulin pump therapy. A head-to-head trial versus the original insulin aspart formulation in pump therapy did not demonstrate superiority of faster aspart in terms of A1C reduction, but pump settings were not optimized for the pharmacokinetic/pharmacodynamic profile of faster aspart. Nevertheless, meal test and continuous glucose monitoring data suggest that faster aspart is beneficial for postprandial glucose control, and a case study is presented illustrating excellent results using this insulin in pump therapy. Frequent blood glucose monitoring and appropriate patient education are vital for success.<p> 41496 10.2337/cd21-0056 Can faster aspart be used to optimize glycemic control with insulin pump therapy? From expectations to lessons learned after a year of use in the United States document-rn46011 Drugs and Drug Therapy